Many people with prostate cancer can safely receive a shorter, more intensive course of radiation therapy after surgery than has conventionally been used, a new study has found.
NIH launched the RECOVER Initiative to learn why some people have prolonged symptoms or develop new or returning symptoms after the acute phase of infection from SARS-CoV-2.
A drug called 177Lu-PSMA-617 may be a new option for treating advanced prostate cancer. In a large clinical trial, adding the drug—a type of radiopharmaceutical—to standard treatments improved how long participants lived.
Two women with genetic predisposition to stomach cancer participated in a clinical trial at the Center for Cancer Research where their stomachs were removed and kept alive for several days, allowing the researchers to study the development of cancer and the effects of different therapies in unprecedented detail. The goal is to better study stomach cancer under realistic conditions and find novel, effective treatments.
Several years past his WWII military service at Pearl Harbor, following a routine visit to the doctor, Leonard Gardner once again faced imminent mortality—but he didn’t know it until many months later.
In the largest exercise research program of its kind, researchers are poised to turn data into comprehensive maps of the molecular changes in the body.
A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has begun, with the first participants now enrolled in Tennessee.
The Clinical Center at the National Institutes of Health (NIH) in Bethesda, Maryland, is America’s largest hospital devoted entirely to research with people. Here, doctors and researchers seek new ways to diagnose, treat, and prevent disease.
Patients with previously treated colorectal cancer that has spread only to the liver may be eligible to participate in a new clinical trial at the NIH Clinical Center.
A class of immunotherapy drugs called immune checkpoint inhibitors is increasingly being used to treat a wide range of cancers, but they seem to be more effective in some patients more than others.
A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland.
A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland.
Mulcahy was diagnosed with merkel cell carcinoma (MCC) in September of 2016. MCC is a rare, aggressive form of skin cancer in which merkel cells found in the top layer of skin grow out of control to form painless lumps.
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of digital mammography for breast cancer screening, is now open for enrollment.
The National Heart, Lung, and Blood Institute and the National Institute of Allergy and Infectious Diseases launched the REPRIEVE trial to determine whether a daily dose of a cholesterol-lowering statin can reduce the risk of cardiovascular disease in people living with HIV who would not normally be prescribed a statin.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a Phase 1 clinical trial to test an investigational vaccine intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria, West Nile fever and dengue fever, and to hinder the ability of mosquitoes to transmit such infections.
More than 6,500 rare diseases affect humans, of which only a few hundred have any treatment. In total these illnesses affect an estimated 25 million people in the United States.
This one-page guide describes different kinds of clinical studies. It explains why researchers might use them and highlights each type’s strengths and weaknesses.
Ever since being diagnosed in January of ’14, I kind of made it a mission of mine to find out as much as I can, what’s available out there as treatments, trials, and just my way of giving back, whether it helps me directly or somebody who comes after me.
Dr. Madhav Thambisetty of the National Institute on Aging at NIH discusses the role of study partners in Alzheimer's disease clinical trials. A study partner relates her experience in an Alzheimer's trial.
